The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://chiaraskqx008425.wikigdia.com/7580867/retatrutide_vs_tirzepatide_a_comparative_analysis